The list of speakers at the Zermatt Summit is impressive / 8th Zermatt Summit - September 12 - 14, 2019 in Zermatt
plus
Actualités de Lausanne
Debiopharm and BIOASTER join forces to expand research to combat infectious diseases
Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...
plusNew sustainable business models are changing society, bringing hope and creating new jobs / 8th Zermatt Summit - 12th - 14th September 2019 in Zermatt
plusIMD World Competitiveness Ranking: Singapore topples United States as world's most competitive economy
plusDebiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Building-integrated photovoltaics: aesthetic, efficient and widely accepted
Bern (ots) - Within the scope of National Research Programme"Energy Turnaround" (NRP 70), researchers studied photovoltaic systems integrated into the roofs and façades (BIPV) of existing buildings from the point of view of aesthetic, ecological and economic criteria. Their findings: all developers and architects could use this technology for the renovation of ...
plus
Schweizerischer Nationalfonds / Fonds national suisse
Photography: A fresh look at science
Bern (ots) - The 457 entries submitted to the third SNSF Scientific Image Competition jury are online. They offer a behind-the-scenes look at research through stunning images and intriguing videos. The international jury awarded prizes to 15 entries that will be exhibited at the Biel/Bienne Festival of Photography. Now in its third edition, the SNSF Scientific Image Competition has collected more than 1200 photographs and ...
plus#RosaceaNoFilter: Online Influencers Take the Lead in Raising Rosacea Awareness in Galderma's Empowering Rosacea Awareness Month Social Media Campaign
As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this ...
plusDebiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America
Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...
plusSOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine
San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...
plusSAKK - Swiss Group for Clinical Cancer Research
The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor, has awarded its science prize for the ninth time.
plusSchweizerischer Nationalfonds / Fonds national suisse
SNSF image competition 2019: Participate and share unexpected insights into science
Bern (ots) - Following the success of the first two editions, the Swiss National Science Foundation has decided to stage its competition for images and short videos from the world of science for a third time. The best entries will be showcased in various exhibitions and via social media. The over 800 entries in 2017 and 2018, and the enthusiasm generated among the ...
plus
Schweizerischer Nationalfonds / Fonds national suisse
Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence
plusTetra Pak Achieves 50% Renewable Electricity Consumption in Just Two Years Since RE100 Commitment
Lausanne, Switzerland (ots/PRNewswire) - Tetra Pak now obtains half of its global electricity supply from renewable sources, putting the company firmly on course to meet its RE100 commitment of using only renewable electricity across all global operations by 2030. (Logo: https://mma.prnewswire.com/media/632361/Tetra_Pak_Logo.jpg ) (Photo: ...
plusTetra Pak Index 2018 Says Smart Packaging Offers Exciting Opportunities in Fast Growing Online Grocery
Lausanne, Switzerland (ots/PRNewswire) - Smart packaging technologies based on unique digital codes will take both online and off-line grocery in exciting new directions during the next few years, says the Tetra Pak Index 2018, launched today. (Logo: https://mma.prnewswire.com/media/632361/Tetra_Pak_Logo.jpg ) ...
plusGalderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'
Lausanne, Switzerland (ots/PRNewswire) - Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve 'clear' (IGA 0) skin*. In the form of ...
plusThe US overtakes Hong Kong at first place among world's most competitive economies
plusDebiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc. / ABAC develops new targeted antibiotics for patients with severe infections
Lausanne (ots) - Debiopharm Group (TM) announces an investment in antibiotic development with the acquisition of a minority stake in ABAC Therapeutics Inc. This investment was made through the Debiopharm Innovation Fund, its strategic investment fund, and illustrates the synergy between the group companies in the ...
plus
Debiopharm International SA Launches Clinical Trials Website: patients.debiopharm.com
plusEMA grants Orphan Drug Designation to Debiopharm International SA's FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer
Lausanne (ots) - Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug Designation to Debio 1347 for treatment of Biliary Tract Cancer affecting around ...
plusDebiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)
Lausanne, Switzerland (ots) - The clinical trial is in collaboration with the Merck-Pfizer Alliance Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the dosing of the first patient in a Phase Ib study of Debio ...
plusArbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptorelin 6-month Formulation, for Treatment of Central Precocious Puberty (CPP)
Atlanta, GA, USA and Lausanne, Switzerland (ots) - Triptodur(TM), (triptorelin) extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty associated with CPP via a once every six-month intramuscular (IM) injection. Arbor Pharmaceuticals, LLC, a U.S. based specialty ...
plusThe Japanese Cancer Association and Debiopharm Group Announce Winners of the 2017 JCA-Mauvernay Award
Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...
plusGalderma: 'Clear' (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies for the treatment of inflammatory papules and pustules of rosacea were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland. The success of rosacea treatment is ...
plus
Galderma: Combined Use of Rosacea Therapies Ivermectin 1% Cream and Brimonidine 0.33% Gel Evaluated in MOSAIC Study
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg ) "This is the first ...
plusDebiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea
Lausanne (ots) - Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical ...
plusDebiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur(TM), Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)
Lausanne, Switzerland and Atlanta, GA (ots) - Triptodur (TM), (triptorelin) for extended release injectable suspension, has been shown to arrest or reverse the clinical signs of puberty with once every six-month intramuscular injection (IM) dosing for children with CPP Approval brings new CPP treatment formulation ...
plusAlmac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor
Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...
plusDebiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN
Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...
plusGenePOC announces FDA clearance for revogene(TM) instrument and its GBS LB test
Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...
plus
Précédent12345678Suivant